



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Exercise of Options

London: Tuesday, 3 June 2014: Chi-Med announces that it has issued 768,182 ordinary shares of US\$1.00 each (the “Shares”) following the exercise of options by Mr Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med, at an exercise price of GBP1.09 per share on 3 June 2014. The options, granted in June 2005, will lapse after ten years.

Following the issue of the Shares, which are expected to be held as a long term investment by Mr Hogg, Mr Hogg is beneficially interested in 1,088,182 Shares, representing 2.06% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone: +852 2121 8200
Panmure Gordon (UK) Limited Richard Gray Andrew Potts	Telephone: +44 20 7886 2500
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med (LSE:HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.